Zeneca Limited

Imperial Chemical Industries Limited

National Research Development Corporation

Astra Zeneca U.k. Limited

Astrazeneca Ab

Andrew John Barker

Alan Wellington Faull

Jason Grant Kettle

Craig Johnstone

Leslie R Hughes

Peter R Marsham

John Oldfield

Stephen J Pegg

Francis Thomas Boyle

Dearg Sutherland Brown

Clifford David Jones

James Michael Wardleworth

David Michael Andrews

Clive Green

Maurice Raymond Finlay

Robert G Andrew

Compounds of formula (I): which possess cell-cycle inhibitory activity are described.

Imidazo[1,2-A]pyridine having anti-cell-proliferation activity

The invention concerns the use of a compound of formula (I), in which Z, X, T, A, R, R, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, in the treatment of a disease or condition mediated by monocyte chemoattractant protein-1 (MCP-1). Certain of the components of formula (I) are novel and are provided, together with pharmaceutical compositions thereof, as further features of the invention.

Monocyte chemoattractant protein-1 inhibitor compounds

The invention concerns quinazoline derivatives of the formula I

Quinazoline derivatives

Bicyclic pyrrole derivatives as MCP-1 inhibitors

The invention concerns the use of a compound of the formula (I) in which Z, X, T, A, R , R , p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, in the treatment of a disease or condition mediated by monocyte chemoattractant protein-1 (MCP-1). Certain of the components of formula (I) are novel and are provided, together with pharmaceutical compositions thereof, as further features of the invention.

A pharmaceutical composition which comprises a compound of formula (I)

Chemical compounds

The invention concerns pharmaceutically useful indoles of formula (I), in which Z, X, T, A, R,, R,, p and q have any of the meanings defined herein, and their pharmaceutically acceptable salts or in vivo hydrolysable esters, as well as pharmaceutical compositions containing them. The novel compounds possess inhibitory activity against monocyte chemoattractant protein-1 (MCP-1). The invention further concerns the use of such indoles in the treatment of a disease or condition mediated by MCP-1.

Indole derivatives as MCP-1 receptor antagonists

Quinazoline derivative

4-anilinoquinazoline derivatives bearing a heteroaryl substituted at the

The invention concerns quinazoline derivatives of the formula I ##STR1## wherein X.sup.1 is a direct link or a group such as CO, C(R.sup.2).sub.2 and CH(OR.sup.2); wherein Q.sup.1 is phenyl, naphthyl or a 5- or 6-membered heteroaryl moiety and Q.sup.1 optionally bears up to 3 substituents; wherein m is 1 or 2 and each R.sup.1 may be a group such as hydrogen, halogeno and trifluoromethyl; and wherein Q.sup.2 may be phenyl or a 9- or 10-membered bicyclic heterocyclic moiety and Q.sup.2 optionally bears up to 3 substituents; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer.

The invention concerns quinazoline compounds of the formula I ##STR1## wherein Q.sup.1 is a 5- or 6-membered heteroaryl moiety and Q.sup.1 optionally bears up to 3 substituents;

Quinazoline compounds

The invention concerns quinazoline derivatives of the formula I ##STR1## wherein m is 1, 2 or 3 and each R.sup.1 includes hydroxy, amino, carboxy, carbamoyl, ureido, (1-4C)alkoxycarbonyl, N-(1-4C)alkylcarbamoyl, N,N-di-[(1-4C)alkyl]carbamoyl, hydroxyamino, (1-4C)alkoxyamino, (2-4C)alkanoyloxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy and (1-3C)alkylenedioxy;

Growing community of inventors

Macclesfield, United Kingdom

Andrew John Barker